AR002350A1 - Composiciones farmacéuticas que contienen irbesartan - Google Patents

Composiciones farmacéuticas que contienen irbesartan

Info

Publication number
AR002350A1
AR002350A1 AR10297996A AR10297996A AR002350A1 AR 002350 A1 AR002350 A1 AR 002350A1 AR 10297996 A AR10297996 A AR 10297996A AR 10297996 A AR10297996 A AR 10297996A AR 002350 A1 AR002350 A1 AR 002350A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
compositions containing
containing irbesartan
irbesartan
pharmaceutical
Prior art date
Application number
AR10297996A
Other languages
English (en)
Inventor
Cathy C Ku
Omar L Sprockel
Beth A Rubitski
Divyakant S Desai
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23876256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR002350(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR002350A1 publication Critical patent/AR002350A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AR10297996A 1995-06-07 1996-06-06 Composiciones farmacéuticas que contienen irbesartan AR002350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47261895A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
AR002350A1 true AR002350A1 (es) 1998-03-11

Family

ID=23876256

Family Applications (2)

Application Number Title Priority Date Filing Date
AR10297996A AR002350A1 (es) 1995-06-07 1996-06-06 Composiciones farmacéuticas que contienen irbesartan
ARP060102579A AR054782A2 (es) 1995-06-07 2006-06-16 Composiciones farmaceuticas y tabletas que contienen irbesartan en combinacion con un diuretico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP060102579A AR054782A2 (es) 1995-06-07 2006-06-16 Composiciones farmaceuticas y tabletas que contienen irbesartan en combinacion con un diuretico

Country Status (23)

Country Link
EP (2) EP1275391B1 (es)
JP (1) JP3162626B2 (es)
KR (1) KR100442719B1 (es)
CN (1) CN1149083C (es)
AR (2) AR002350A1 (es)
AT (2) ATE503478T1 (es)
AU (1) AU702651B2 (es)
CA (1) CA2177772C (es)
CZ (1) CZ291532B6 (es)
DE (2) DE69638348D1 (es)
DK (2) DK0747050T4 (es)
ES (2) ES2363127T3 (es)
HK (1) HK1002384A1 (es)
HU (1) HU229369B1 (es)
IL (1) IL118309A (es)
NO (2) NO310495B1 (es)
NZ (2) NZ286612A (es)
PL (1) PL184893B1 (es)
PT (2) PT747050E (es)
RU (2) RU2181590C2 (es)
SG (1) SG49956A1 (es)
TW (1) TW442301B (es)
ZA (1) ZA964337B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4575594B2 (ja) * 1998-07-20 2010-11-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 経口用固体剤形のエプロサルタン配合の生体内強化性処方
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
EP1648515B1 (en) * 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidone combinations
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
JP2005126338A (ja) * 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
WO2006013545A1 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Pharmaceutical compositions of irbesartan
SI1928409T1 (sl) 2005-09-12 2012-12-31 Actelion Pharmaceuticals Ltd. Stabilni farmacevtski sestavek, ki obsega pirimidin-sulfamid
JP2009515993A (ja) * 2005-11-17 2009-04-16 ノバルティス アクチエンゲゼルシャフト 医薬組成物
DE602006013261D1 (de) * 2006-01-09 2010-05-12 Krka D D Irbesartan enthaltende feste Zubereitung
DE102006006588A1 (de) * 2006-02-13 2007-08-16 Ratiopharm Gmbh Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung
CL2007001714A1 (es) * 2006-06-12 2008-01-18 Schering Corp Composicion farmaceutica que comprende 2-hidroxi-n,n-dimetil-3-[[2-[[1(r)-5-metil-2-furanil)propil]amino]-3,4-dioxi-1-ciclobuteno-1-il]amino]benzamida y al menos un excipiente seleccionado de un agente humectante, un aglutinante, un disolvente y un desintegrante, util para tratar una enfermedad inflamatoria tal como artritis y asma.
US8685452B2 (en) 2006-06-16 2014-04-01 Lek Pharmaceuticals D.D. Pharmaceutical composition
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
RU2465900C2 (ru) * 2007-04-17 2012-11-10 Рациофарм Гмбх Фармацевтические композиции, содержащие ирбесартан
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
PT2065035E (pt) 2007-11-28 2010-10-04 Lesvi Laboratorios Sl Formulações farmacêuticas contendo irbesartan
CN101327213B (zh) * 2008-06-20 2010-10-13 海南锦瑞制药股份有限公司 厄贝沙坦氢氯噻嗪药用组合物及其制备方法
JP5296456B2 (ja) * 2008-08-26 2013-09-25 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
WO2010075347A2 (en) * 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
PE20121131A1 (es) * 2009-06-30 2012-09-04 Sanofi Sa Composicion farmaceutica oral solida en comprimido monocapa que comprende irbesartan y besilato de amlodipina
WO2011010316A1 (en) * 2009-07-20 2011-01-27 Hetero Research Foundation Pharmaceutical compositions of irbesartan
HUE046606T2 (hu) * 2009-11-09 2020-03-30 Wyeth Llc Neratinib maleát tabletta formái
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
JP4974255B2 (ja) * 2010-03-16 2012-07-11 塩野義製薬株式会社 アンジオテンシンｉｉ受容体拮抗剤の配合剤
JP5459670B2 (ja) * 2010-05-07 2014-04-02 塩野義製薬株式会社 着色顆粒の色素定着化剤
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
EP2929877A1 (en) * 2010-07-08 2015-10-14 ratiopharm GmbH Oral dosage form of deferasirox
JP6081376B2 (ja) * 2011-12-28 2017-02-15 ニプロ株式会社 アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物
US10952968B2 (en) 2012-05-14 2021-03-23 Shionogi & Co., Ltd. Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide
JP5714652B2 (ja) * 2013-06-13 2015-05-07 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6238921B2 (ja) * 2014-02-17 2017-11-29 大原薬品工業株式会社 イルベサルタンを含有する錠剤
JP5978335B2 (ja) * 2015-03-11 2016-08-24 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6199922B2 (ja) * 2015-03-20 2017-09-20 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
JP6445923B2 (ja) * 2015-04-22 2018-12-26 ダイト株式会社 イルベサルタン含有錠剤の調製方法
JP6737060B2 (ja) * 2015-09-11 2020-08-05 ニプロ株式会社 イルベサルタンを含有する医薬組成物の製造方法
JP6151413B2 (ja) * 2016-07-25 2017-06-21 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2017141299A (ja) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6233911B2 (ja) * 2017-08-22 2017-11-22 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
JP2018009032A (ja) * 2017-10-19 2018-01-18 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
CN108434112A (zh) * 2018-06-08 2018-08-24 华益药业科技(安徽)有限公司 一种厄贝沙坦片及其制备方法
JP2018168185A (ja) * 2018-07-05 2018-11-01 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
PH12018000390A1 (en) * 2018-11-20 2020-09-28 Novex Science Pte Ltd Carbocysteine and zinc tablet
JP2019203031A (ja) * 2019-09-06 2019-11-28 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3744317C1 (de) 1987-12-28 1989-05-24 Rudolf Dr Rer Nat Kuerner Verwendung von Calciumsulfat zur Verbesserung der Fermentierung organischer Abfallstoffe
CA2016710A1 (en) 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
US5164407A (en) 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
TW201738B (es) * 1990-03-20 1993-03-11 Sanofi Co
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
CA2061607C (en) 1991-02-21 1999-01-19 Hiroaki Yanagisawa 1-biphenylimidazole derivatives, their preparation and their therapeutic use
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
AU5449194A (en) 1992-10-26 1994-05-24 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Also Published As

Publication number Publication date
ZA964337B (en) 1997-11-28
DE69629755D1 (de) 2003-10-09
CN1149083C (zh) 2004-05-12
AU5476396A (en) 1996-12-19
ES2205000T3 (es) 2004-05-01
DE69629755T2 (de) 2004-07-01
CN1144656A (zh) 1997-03-12
HK1002384A1 (en) 1998-08-21
MX9602103A (es) 1997-09-30
NZ329547A (en) 1998-06-26
DE69638348D1 (de) 2011-05-12
NO20004743D0 (no) 2000-09-22
DK0747050T4 (da) 2013-05-21
DK0747050T3 (da) 2003-12-15
NO20004743L (no) 1996-12-09
EP0747050B1 (en) 2003-09-03
ES2205000T5 (es) 2013-05-30
ATE503478T1 (de) 2011-04-15
RU2181590C2 (ru) 2002-04-27
EP0747050A1 (en) 1996-12-11
HUP9601564A2 (hu) 1998-09-28
CZ291532B6 (cs) 2003-03-12
EP0747050B2 (en) 2013-02-13
IL118309A (en) 2003-06-24
AU702651B2 (en) 1999-02-25
SG49956A1 (en) 1998-06-15
NO310393B1 (no) 2001-07-02
PT747050E (pt) 2003-12-31
EP1275391B1 (en) 2011-03-30
CA2177772A1 (en) 1996-12-08
DK1275391T3 (da) 2011-07-11
NO962387D0 (no) 1996-06-06
HU229369B1 (en) 2013-11-28
ES2363127T3 (es) 2011-07-21
HU9601564D0 (en) 1996-08-28
ATE248594T1 (de) 2003-09-15
CZ163496A3 (en) 1996-12-11
TW442301B (en) 2001-06-23
DE69629755T3 (de) 2013-08-08
PT1275391E (pt) 2011-06-30
KR100442719B1 (ko) 2004-10-08
NO962387L (no) 1996-12-09
PL314670A1 (en) 1996-12-09
RU2001130903A (ru) 2004-02-27
RU2210368C1 (ru) 2003-08-20
EP1275391A1 (en) 2003-01-15
JP3162626B2 (ja) 2001-05-08
HUP9601564A3 (en) 2000-12-28
AR054782A2 (es) 2007-07-18
PL184893B1 (pl) 2003-01-31
IL118309A0 (en) 1996-09-12
NO310495B1 (no) 2001-07-16
JPH08333253A (ja) 1996-12-17
CA2177772C (en) 2007-04-10
KR970000232A (ko) 1997-01-21
NZ286612A (en) 1998-03-25

Similar Documents

Publication Publication Date Title
AR002350A1 (es) Composiciones farmacéuticas que contienen irbesartan
CY2005007I2 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
IS4706A (is) Lyfjasamsetningar
NO20021172D0 (no) Farmasöytisk sammensetning
FI973518A (fi) Farmaseuttinen koostumus piperidinoalkanoliyhdisteille
ITRM960810A0 (it) Composizioni farmaceutiche contenenti ciclosporine o macrolidi
FI974241A0 (fi) BPM-15 -koostumukset
DE69610553T2 (de) Deodorant zusammensetzungen
NO981568D0 (no) Randtennings-tennsatssammensetninger
BR9610214A (pt) Compostos farmacéuticos
DE69617029D1 (de) Organoton-zusammensetzungen
FR2732592B1 (fr) Compositions cosmetiques autobronzantes
IL118424A0 (en) Pharmaceutical compositions containing benzimidazole derivative
DE69614407T2 (de) Pharmazeutische zusammensetzungen
EE9800400A (et) Diklofenaaki sisaldavad farmatseutilised kompositsioonid
LV11727A (lv) Farmaceitiska kompozicija
EE9900206A (et) N-sulfonüülindoliiniderivaate sisaldavad farmatseutilised kompositsioonid
FI973280A (fi) Farmaseuttinen koostumus
DE69605016D1 (de) Intumeszenzzusammensetzung
DE69603228D1 (de) Aluminoxanate-Zusammensetzungen
ATE206150T1 (de) Farbstoffstabilisierte zusammensetzungen
NO965448L (no) Farmasöytiske forbindelser
BR9605777A (pt) Composição farmacêutica
BR9605131A (pt) Composição farmacêutica
DE69615571T2 (de) Farbstoffstabilisierte zusammensetzungen

Legal Events

Date Code Title Description
FC Refusal